Microdose (≈0.5–4 mg) in studies; pharmaceutical grade only, never the aquarium kind.
Randomized trial with fMRI (26 people): a low oral dose of methylene blue increased the brain response in sustained-attention and short-term memory tasks. Small study with an indirect measure (imaging), without a clear clinical outcome.
View the study (study) →⏱ 2 min read
Methylene blue is a synthetic dye with a medical history of more than 130 years: it was one of the first modern synthetic drugs, originally used to treat malaria in the late nineteenth century, and since then it has had multiple clinical applications as an antidote for methemoglobinemia (where it is the treatment of choice at high doses), a urinary antiseptic, a surgical stain, and, in recent neurological research, as a mitochondrial modulator and neuroprotectant at very low doses (microdoses); modern clinical interest in microdoses stems from a peculiar pharmacological property: at low concentrations, methylene blue acts as an alternative electron acceptor in the mitochondrial respiratory chain, "bypassing" enzymatic defects and improving ATP production in tissues with mitochondrial dysfunction, a property that motivates its study in neurodegenerative diseases and in brain aging.
Several small studies have documented acute improvements in memory and attention with low doses of methylene blue (0.5-4 mg/kg, equivalent to 35-280 mg in an adult) in healthy adults and in people with mild cognitive impairment; functional magnetic resonance imaging studies have shown increased activity in brain areas related to episodic memory, an observation consistent with the mitochondrial mechanistic profile.
In Alzheimer's disease, several clinical trials with stabilized methylene blue derivatives (LMTX, LMTM, or hydromethylthionine) have shown heterogeneous results but with favorable trends in some subpopulations; research in this indication is active, with interesting preliminary data.
Unlike therapeutic pharmacological doses (1-2 mg/kg for methemoglobinemia), "nootropic" microdoses are typically 0.5-4 mg per day (not per kg), figures several tens of times lower than pharmacological ones and with a significantly better tolerability profile; methylene blue as a nutritional supplement is in an ambiguous regulatory zone in many countries, and it is wise to verify local legal availability before purchasing products.
Typical nootropic doses are 0.5-4 mg/day orally, in a single morning dose (it can cause insomnia if taken late); USP/pharmacopeial pharmaceutical products are significantly purer and safer than non-pharmaceutical industrial products; methylene blue turns the urine, and sometimes the tongue, a blue-green color, a benign but striking cosmetic effect.
The precautions are significant: methylene blue is absolutely contraindicated with serotonergic drugs (SSRIs, SNRIs, MAOIs, triptans, tramadol, others) because of the risk of severe serotonin syndrome (methylene blue is a potent MAO-A inhibitor); people with glucose-6-phosphate dehydrogenase deficiency can develop severe hemolysis; people with serious kidney failure should avoid methylene blue; it is contraindicated in pregnancy (teratogenicity data); data in breastfeeding are limited; high doses or prolonged microdose use without medical supervision is not prudent; the choice between pure pharmaceutical products and commercial nutritional products is important because quality varies enormously and industrial products may contain problematic contaminants (heavy metals, other dyes); the reasonable clinical position is to consider methylene blue an experimental intervention with an interesting mechanistic basis but a complex clinical-use profile, preferably reserved for research or use under specialized medical supervision, not as a routine nutritional supplement.
Information, not medical advice. Scientific evidence reflects the quality of the studies.